Alexion hires new chief commercial officer
Goff is currently chief operating officer at neuroscience company Neurovance, which Otsuka Pharmaceutical acquired for $100 million this March.
Alexion Pharmaceuticals appointed Brian Goff as its new chief commercial officer, effective June 1, as part of an executive shake-up underway at the drugmaker.
Goff is currently chief operating officer at neuroscience company Neurovance, which Otsuka Pharmaceutical acquired for $100 million this March. Goff has also held senior executive roles at Baxalta, Baxter, and Novartis. He replaces Carsten Thiel, who is leaving Alexion to pursue new opportunities, according to the drugmaker.
“I am very excited to join Alexion and have long admired the company's leadership in rare diseases, commitment to breakthrough medical innovation, patient-centric focus, and successful growth trajectory,” said Goff, in a news release.
The appointment comes along with a number of other leadership changes, including the departure of CFO Dave Anderson, EVP and head of research and development Martin Mackay, and EVP and chief human resources officer Clare Carmichael. Alexion said recruitment is underway for all three positions.
Current Alexion CEO Ludwig Hantson has only been in his role since March. Previously CEO of Baxalta, Hantson succeeded interim-chief David Brennan when former CEO David Hallal and CFO Vikas Sinha resigned in December, a month after the drugmaker said it was investigating the sales practices of its flagship drug Soliris. A former employee has alleged that Alexion's senior management pushed its staff to order the drug to meet financial targets.
Geoffrey Porges, an analyst at investment bank Leerink Partners, said in a research note, that the executive departures are part of Hantson's aim to “completely break with past leadership," as reported by MarketWatch.
Alexion reported $870 million in revenue in the first quarter of 2017, a 24% increase when compared to the same period in 2016. This was driven by $783 million in revenue from Soliris, sales of which grew 18% year over year.